Archives — Current Month (8)

Coverage Initiated on 'Emerging Antibiotics Growth Story with Multiple Levers for Upside' (09/19/2018)

An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm.


Cancer Vaccine Developer Expands Its Collaboration with Merck (09/19/2018)

A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner.


U.S. Biotech Partner Obtains Marketing Authorization for ADHD Treatment in Taiwan (09/18/2018)

Permission has been obtained to distribute time-release capsules.


Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment (09/14/2018)

With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center.


Canadian Biopharma to Outlicense Pain Drug to South Korean Firm (09/12/2018)

An Echelon Wealth Partners report discussed the deal terms.


Biopharma's Positive FDA Meeting Outlines Path Forward for Trial (09/11/2018)

A ROTH Capital Partners note explained the outcome of the tÍte-a-tÍte and its implications.


Coverage Initiated on Firm with Paradigm-Shifting Colonoscopy Device (09/05/2018)

A Ladenburg Thalmann report covered the asset, product market and financial projections of this Florida-based company.


Final Approval of Biopharma's Lead Candidate Both Likely and Imminent (09/05/2018)

A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication.


More Archives

2018Aug Jul Jun May Apr Mar Feb Jan

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2013Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes

"PMN anticipates launching its first in-human trial in 2019 of PMN310."
– John Vandermosten, Zacks Small-Cap Research